OCM
TXG icon

Osbon Capital Management’s 10x Genomics TXG Stock Holding History

Osbon Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5K Hold
300
– – 0.01% 263
2026
Q1 		$6.37K Buy
+300
New +$6K 0.01% 341

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osbon Capital Management's TXG Position: Q2 2026 in Review

Osbon Capital Management held its 10x Genomics (TXG) position steady in Q2 2026 at 300 shares worth $11.5K. The position accounts for 0.01% of the portfolio, ranked #263.

Osbon Capital Management first reported a position in TXG in Q1 2026 and has held it in 2 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Osbon Capital Management held 300 shares of 10x Genomics worth $11.5K as of Q2 2026.
  • Osbon Capital Management left its 10x Genomics share count unchanged in Q2 2026.
  • 10x Genomics made up 0.01% of Osbon Capital Management's portfolio in Q2 2026, its #263 holding.
  • Osbon Capital Management first reported a position in 10x Genomics in Q1 2026 and has held it in 2 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Osbon Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.